Introduction
Nocebo refers to adverse events (AEs) connected to negative expectations that medical treatment will probably harm instead of heal and can be assessed in placebo-controlled randomized clinical trials (RCTs) [1, 2] . The nocebo effect is related to lower adherence in therapy, high rates of dropouts, as well as significant difficulty in assessing the efficacy and the safety profile of a drug in clinical trials [3, 4] . There is evidence that nocebo is related to negative pretrial suggestions and previous negative experiences during treatment [5] along with several psychological factors including stress and anxiety [6] [7] [8] .
Nocebo has been studied in RCTs for several neurological conditions, including multiple sclerosis [9] , headache [10, 11] , neuropathic pain [12] , fibromyalgia [1] , diabetic peripheral neuropathy [13] , Parkinson's disease [14] , depression [2, 15] and Alzheimer's disease [16] . In these studies dropouts because of AEs in placebo treated patients varied from 2% (in multiple sclerosis) to almost 10% (in Parkinson's disease and fibromyalgia). These rates indicate significant implications for clinical practice related to adherence and treatment outcome.
The aim of our study was to estimate the frequency and strength of nocebo effects in epilepsy trials. The dropout rate of epilepsy sufferers because of placebo-related AE was used as a measure of severity of the nocebo effect.
Methods
A computer-based literature search was conducted on January 7th, 2016 on PubMed using "epilepsy", "treatment" and "placebo" as search words. Limitations included article type to be Clinical Trial, text availability to be Full text, Species to be Humans and Language to be English. We further filtered the search for pharmacotherapy and RCTs. All selected studies that were relevant were selected for analysis [17] .
Inclusion criteria
To be included in our analysis the articles had to meet the following criteria; (i) they referred specifically to epilepsy and not any other disease where anti-epileptic medications are used (i.e. neuropathic pain), (ii) they were pharmaceutical studies, (iii) they were RCTs, (iv) there was a purely placebo arm, (v) they involved adults, (vi) primary outcome was seizure control and (vii) there was a washout period, where applicable.
Data extraction
Data were extracted from each study in a structured coding scene using excel and included information on the article identification, year of publication, evaluation period, epilepsy type, total number of subjects, washout period (where applicable), number of placebo-treated subjects, number of placebo-treated subjects who dropped out because of seizure activity, number of placebo-treated subjects who dropped out because of AEs, number of male subjects treated with placebo, mean age of placebo-treated subjects, number of active drug-treated subjects, number of active drug-treated subjects who dropped out because of seizure activity, number of active drug-treated subjects who dropped out because of AEs, number of male subjects treated with active drug, mean age of active drug-treated subjects, active drug, way of administration and country. We calculated the nocebo AE rates or dropout rates for each group by pooling the percentage of placebo-treated or active drug-treated patients respectively, who had at least one AE or dropped out because of AE.
Statistical analyses
A database was developed using the IBM SPSS Statistics (version 23.0 for Mac). Frequencies and descriptive statistics were examined for each variable. The outcomes of interest were the proportion of patients receiving active drug and the proportion of patients receiving placebo who experienced AEs and the proportion of patients receiving placebo and the proportion of patients receiving active drug who dropped out of the study because of any AE.
The meta-analysis was conducted using the RevMan programme (Review Manager, Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) as suggested by the Cochrane Collaboration Group.
Heterogeneity between studies was assessed by I [2] . Data were analyzed using a random effects model.
Results
The process of the article selection is presented in Fig. 1 . From the 621 articles retrieved, 4 monotherapy placebo controlled RCTs were considered in the final analysis [18] [19] [20] [21] . All studies involved patients with refractory partial epilepsy who where admitted for pre-surgical monitoring. These studies were published between 1995 and 2000 and they involved 125 placebo-treated patients with epilepsy. The main characteristics of the studies and their populations are presented in Table 1 .
Adverse events in placebo and active drug groups
The pooled estimate of the percentage of placebo treated patients who withdrew treatment was 76.8% (95% CI 68.4%-83.9%). The pooled estimate of the percentage of placebo treated patients who withdrew treatment because of seizures was 70.4% (95% CI 61.6%-78.2%). The pooled estimate of the percentage of placebo treated patients who withdrew treatment because of AEs was 3.2% (95% CI 0.9%-8.0%).
The pooled estimate of the percentage of active drug treated patients who withdrew treatment was 52.1% (95% CI 42.8%-61.2%). The pooled estimate of the percentage of active drug treated patients who withdrew treatment because of seizures was 42.1% (95% CI 33.2%-51.5%). The pooled estimate of the percentage of active drug treated patients who withdrew treatment because of AEs was 8.3% (95% CI 4.0%-14.7%).
Only two of the studies reported in detail the number [19, 20] and three studies [18] [19] [20] reported the nature of AEs in the study groups. The pooled estimate of the percentage of placebo treated patients with at least one AE was 60.8%, in comparison to 76.0% for active drug treated patients. The most commonly reported AE in the placebo treated patients was headache [18, 20] and dizziness [19] , in comparison to headache, nausea [18, 20] and dizziness [19] in active drug treated patients.
As illustrated in the forest plot (Fig. 2a) , placebo reduced by 58% (95% CI À87% to +57%) the chance of dropping out because of an adverse event other than seizure activity. This is a non-statistically significant difference.
As shown in the funnel plot (Fig. 2b) there was no heterogeneity among the studies included in the meta-analysis.
Discussion
Nocebo varies among neurological conditions. Although comparisons are difficult because of differing trial populations and pathophysiology of the diseases, it is still useful to underpin the picture of nocebo magnitude in the disorders of the nervous system. Using identical methodology, it was found that the nocebo AE rate ranges from 42.8% in headache trials [10] to 74.4% in MS trials [9] , and the nocebo dropout rate ranges from 2.1% in MS trials [9] to almost 10% in fibromyalgia and Parkinson disease trials [1, 14] . Comorbidity with somatoform disorders and changes in dopamine pathways within the brain may account for this variation [1, 14] . Several other factors may influence nocebo, such as the route of drug administration [10] , but no available data exist to search for a similar manipulation in epilepsy RCTs, since all studies included in our meta-analysis used oral administration.
Previously, other research teams have tried to investigate the nocebo effect in epilepsy, however in these approaches the researchers included studies where placebo was compared to an active drug as an add-on treatment. Zaccara et al. have investigated the nocebo effect by analyzing placebo-treated, drug-resistant, focal epileptic patients in RCTs [22] . They estimated that the proportion of placebo-treated patients withdrawing because of AEs was 3.9%, and proportion of patients with AE was 60.3% [22] . Zaccara et al. have also investigated the nocebo effect in pediatric patients [23] . Similar to adults, the proportion of placebo-treated patients withdrawing because of AEs was 3.6%, however the proportion of patients with AE was 81.3% [23] . Recently, Zaccara et al. analyzed the nocebo effects of antiepileptic drugs across different conditions and they showed that significant differences have been identified in the nocebo effect across different conditions [24] . Therefore, the nocebo effect is more disease specific than medication specific and it is important to be evaluated independently in each disorder. The uniqueness of our study is that we focused specifically to epilepsy and we included trials of all potential antiepileptic treatments as a monotherapy. Thus, we managed to estimate the nocebo effect in patients not receiving any active anti-epileptic treatment (something that happens when placebo is compared with an active drug in add-on studies), which may cause AEs. Interestingly, our results estimated the nocebo effect to be the same with the ones that Zaccara et al. estimated when analyzing add-on epilepsy RCTs [22, 23] .
Limitations
Our results should be interpreted with some caution given the limitations of our design. Firstly, although our measures of nocebo were calculated from the trial drop-outs designated as drug toxicity-related and the AEs that were classified as drug-related, the inherent difficulty in attributing non-specific symptoms has to be recognized as a potential source of bias. Secondly, nocebo severity is indirectly estimated using dropout rate as a proxy. Thirdly, the heterogeneity in the incidence of AEs and the dropout rate limits the applicability of the pooled estimates of nocebo responses. Also, not all studies provided detailed information about when exactly the AEs occurred. Finally, this meta-analysis was performed using only 4 RCTs, which involved monotherapy in refractory partial epilepsy over a short period of time in the presurgical monitoring setting. Therefore our estimate may not reflect the extent of the nocebo effect in all patients with epilepsy. However, these were the only studies meeting our inclusion criteria since there are no large RCTs over longer periods of time and in other types of epilepsy available. 
Implications for trial design
Prospective, randomized, placebo-controlled, double blind studies are the gold standard for epilepsy trials. The wide availability of anti-epileptic agents makes purely placebo-controlled trials unethical and therefore, the newer RCTs are add-on studies. As our results are very similar to the results of the metaanalysis conducted by Zaccara et al. [22] , which also included the add-on studies, it is probably safe to conclude that one in 30 participants in RCTs for epilepsy would discontinue treatment because of nocebo. The lower percentages and rates of AEs found in the placebo-treated patients as opposed to the active drug-treated ones seem to fit our expectations and predictions because a dummy drug (chemically inactive) should not cause more exaggerated and intense issues to patient compliance as far as their medication regimen is concerned [14] . On the other hand the higher percentage of dropouts in total-contrary to the expectations and what meta-analyses have shown in other neurological diseases, can be explained by the fact that patients who receive placebo are untreated and will withdraw because of higher frequency of seizures.
Implications for clinical practice
The consequences of nocebo in clinical practice are important, as current treatment of epilepsy is based upon evidence possibly confounded by nocebo. This meta-analysis does not provide any direct evidence for nocebo in clinical practice. But, as long as RCT findings predict the effectiveness and the safety of a treatment in clinical practice, this post hoc safety analysis may provide important considerations relevant to daily clinical practice as well. In any case, clinicians should be aware that drug intolerance and treatment failure might be caused by nocebo and recruit individualized strategies to limit it [25] .
Nocebo arises from the patient's expectations or previous learning experiences [26] . Apart from psychological mechanisms, central mediators such as dopamine an endogenous opiates are likely to play a key part in the mediation of the nocebo phenomenon. Finally, a genetic predisposition to placebo response has been demonstrated in few diseases such as depression and anxiety and -therefore -the same may apply to the nocebo effect [26] .
Conclusion
In RCTs for refractory partial epilepsy three of five participants report AEs related to nocebo, although they seem to be drug related. These AEs are significant enough to cause treatment withdrawal in almost one of 30 participants. Therefore, nocebo deserves much attention in the context of both clinical trial design and clinical practice.
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